Oncology

News

Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.

News

Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.

News

Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.

News

GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.

News

As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.

News

New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.